IQ Consortium
Organization of pharmaceutical and biotechnology companies with a mission of advancing science and technology.
Vision
The vision of the International Consortium for Innovation and Quality in Pharmaceutical Development is to be the leading science-based organization advancing innovative solutions to biomedical problems and enabling pharmaceutical companies to bring quality medicines to patients.
Mission
As a technically-focused organization of pharmaceutical and biotechnology companies, IQ advances science and technology to augment the capability of member companies to bring transformational solutions that benefit patients, regulators and the broader R&D community.
Strategic Objectives
- Collaborate across IQ member companies to create cross-functional data sets, scientific positions and conclusions with greater scope and impact than possible by any member company alone;
- Advance relationships with global professional organizations, other consortia, academics and government research institutes to ensure scientific excellence and harmonization;
- Proactively build consensus with global regulators on issues and opportunities to advance innovation and quality in pharmaceutical development;
- Share the results of IQ’s initiatives with international scientific and regulatory communities;
- Ensure the continued value of IQ through committed leadership, focused and clear priority-setting, productive cross-disciplinary collaborations, and active engagement by a diverse talent pool to plan for leadership succession.
IQ Consortium Leadership
IQ Consortium is governed by a Board of Directors, comprised of representatives from all IQ member companies and is led by a Chair and Vice-Chair.
IQ Consortium Chair
Philip Floyd, Ph.D.
AbbVie
Phil currently serves as Global VP, Analytical Research and Development at AbbVie overseeing a department of approximately 230 scientists in the development of the small molecule portfolio. Prior to AbbVie, he served as Senior Director of US Analytical Development at GSK overseeing both large and small molecule development in two sites within Pennsylvania. While at GSK, Phil also spent several years in RTP North Carolina at Team Leader with a mixed development team of formulators and analysts. Prior to this time Phil worked as bench analyst at both GSK and J&J.
Phil grew up in Oklahoma and received his BS in Chemistry at the University of Oklahoma. After graduation, he attended the University of Illinois at Urbana-Champaign and received his PhD in Analytical Chemistry under Jonathan Sweedler. While at Illinois, he performed the research for his dissertation at the Beckman Institute of Technology, working collaboratively with varying disciplines, such as Molecular and Cellular Biology, Computational Chemistry, Engineering, and Physical Chemistry, in performing quantitative analysis and characterization of peptides and proteins within neuronal signaling pathways.
Phil has over 40 scientific presentations over 20 publications in peer-reviewed journals. He currently serves as Chair of the IQ Consortium.
IQ Consortium Vice-Chair
Jens Sydor, Ph.D.
GSK
Dr. Jens Sydor is Vice President, Drug Metabolism and Pharmacokinetics at GSK. His global DMPK organization supports the whole GSK pipeline from early Discovery to post-submission. The main focus is on Discovery in vitro/in vivo ADME science, mechanistic in vitro/in vivo ADME studies, translational PKPD and PBPK modeling for the prediction of human outcomes.
During his career in the biotech/pharma sector since 1999, Jens has contributed to the discovery and development of several pharmaceutical products as well as leading many organizations successfully through change. He has also been a longstanding member of the IQ TALG, holding the vice-chair and chair position from 2019-2022.
Jens received his Ph.D. from the Max-Planck-Institute for molecular physiology in 1998.
IQ Members
AbbVie
Agios
Alkermes
Alnylam
Amgen, Inc.
Astellas
AstraZeneca
Avidity Biosciences
Bayer HealthCare
BeOne Medicines
Bill & Melinda Gates MRI
Biogen
BioMarin
Blueprint Medicines
Boehringer Ingelheim
Bristol Myers Squibb
Callio Therapeutics
Crinetics Pharmaceuticals
CSL Behring
Daiichi Sankyo
Eisai, Inc.
Eli Lilly and Company
EMD Serono
Erasca, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche
Genentech
Gilead Sciences
GSK
IDEAYA Biosciences
Incyte Corporation
Johnson & Johnson
Kura Oncology
Kymera Therapeutics
Merck & Co., Inc.
Mitsubishi Tanabe
Moderna Therapeutics
Novartis
Novo Nordisk
Organon
Orion Pharma
Otsuka
Pfizer, Inc.
Regeneron
Relay Therapeutics
Sanofi
Sarepta
Servier
Sironax USA
Takeda
Teva
UCB Pharma
Vertex, Inc.
Xencor
Zoetis
Join IQ
IQ membership provides companies with access to a sustained forum for the exchange of ideas within the pharmaceutical and biotechnology industries. Members lead and participate in collaborative research, industry surveys and benchmarking exercises, as well as ongoing external collaborations with governmental bodies, other trade groups, and academic researchers. Consortium publications, scientific conferences, workshops and roundtables increase members’ presence in these communities.
Any corporation and/or any subsidiary thereof, which is significantly engaged in the development of new chemical entities or new molecular entities for the prevention, diagnosis or treatment of disease is eligible for membership in the IQ Consortium. For purposes of this provision, “significantly engaged” shall mean that a company is currently sponsoring at least one active Clinical Trial Application for a new chemical entity or new molecular entity.
To find out how your company can join the Consortium or, if you work at a company that is already a member and are interested in learning more about participation, please contact us!
